The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) ...

The British Society for Rheumatology has moved toward a life course approach when updating guidelines for several rheumatic ...

Not unlike Regeneron's acquisition of 23andMe, Predictive Oncology's AI-driven breakthroughs reflect a broader transformation ...

The NIFTY MIDCAP 150's movements reflect ongoing market dynamics, with Global Health, JSW Infra, and GlaxoSmithKline ...

Stocks from pharmaceutical companies and healthcare spaces dominated analysts' choices for Thursday's trading session.

ICICI Securities recommended reduce rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2,600 in its research ...

Current treatment paradigms for lupus nephritis offer significant room for improvement, according to a presenter at the ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

The fall of 23andMe raises privacy concerns as Regeneron buys its genetic database for $256M after bankruptcy.

Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

UnitedHealth CEO Andrew Witty is stepping down for personal reasons and the nation’s largest health insurer suspended its ...